Yin Weidong, Sinovac CEO (Nicolas Bock/Bloomberg via Getty Images)

Covid-19 roundup: Sino­vac shot com­plete­ly pre­vents se­vere cas­es at 14-day mark, com­pa­ny says

Sino­vac has made some big da­ta claims on its way to a ten­ta­tive ap­proval in Chi­na for its Covid-19 vac­cine. New Phase III da­ta show promis­ing re­sults in pre­vent­ing se­vere dis­ease, but will it be enough to con­vince in­ter­na­tion­al reg­u­la­tors?

Phase III tri­als of the vac­cine, al­so called Coro­n­aVac, be­gan back in Ju­ly and were on­go­ing in Brazil, Turkey, In­done­sia and Chile us­ing a 0/14 day sched­ule with a to­tal en­roll­ment of 25,000 par­tic­i­pants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.